TNF and Opportunistic infection: When using biologics, the risk of bacterial and opportunistic infections is greater, but this risk mainly concerns anti-tumor necrosis factor (TNF) agents, while ustekinumab and vedolizumab probably have a more favorable safety profile (9–11).